Key result
Genetically predicted higher serum phosphate is linked to increased coronary artery calcification without chronic kidney disease.
Why the study?
Hyperphosphatemia is associated with CAC mainly in chronic kidney disease, but the association within the normal phosphate range and its causality remain unclear.
Does higher serum phosphate increase coronary artery calcification in the general population?
Cohort (n=1,889)
No
Does higher serum phosphate increase coronary artery calcification in the general population?
Effect estimate: β 0.93 (95% CI 0.07-1.79)
p-value: p=0.034
Higher serum phosphate levels within the normal range are causally associated with increased coronary artery calcification, particularly in men, challenging the concept that only severe hyperphosphatemia in CKD drives calcification.
May support phosphate as a CAC risk factor beyond CKD; leaves open whether lowering it reduces events in trials.
Background Hyperphosphatemia has been associated with coronary artery calcification (CAC) mostly in chronic kidney disease, but the association between phosphate levels within the normal phosphate range and CAC is unclear. Our objectives were to evaluate associations between phosphate levels and CAC among men and women from the general population and assess causality through Mendelian randomization. Methods and Results CAC, measured by electron‐beam computed tomography, and serum phosphate levels were assessed in 1889 individuals from the RS (Rotterdam Study). Phenotypic associations were tested through linear models adjusted for age, body mass index, blood pressure, smoking, prevalent cardiovascular disease and diabetes, 25‐hydroxyvitamin D, total calcium, C‐reactive protein, glucose, and total cholesterol : high‐density lipoprotein cholesterol ratio. Mendelian randomization was implemented through an allele score including 8 phosphate‐related single‐nucleotide polymorphisms. In phenotypic analyses, serum phosphate (per 1 SD) was associated with CAC with evidence for sex interaction ( P interaction =0.003) (men β, 0.44 [95% CI, 0.30–0.59]; P =3×10 −9 ; n=878; women β, 0.24 [95% CI, 0.08–0.40]; P =0.003; n=1011). Exclusion of hyperphosphatemia, chronic kidney disease (estimated glomerular filtration rate <60 mL/min per 1.73 m 2 ) and prevalent cardiovascular disease yielded similar results. In Mendelian randomization analyses, instrumented phosphate was associated with CAC (total population β, 0.93 [95% CI: 0.07–1.79]; P =0.034; n=1693), even after exclusion of hyperphosphatemia, chronic kidney disease and prevalent cardiovascular disease (total population β, 1.23 [95% CI, 0.17–2.28]; P =0.023; n=1224). Conclusions Serum phosphate was associated with CAC in the general population with stronger effects in men. Mendelian randomization findings support a causal relation, also for serum phosphate and CAC in subjects without hyperphosphatemia, chronic kidney disease, and cardiovascular disease. Further research into underlying mechanisms of this association and sex differences is needed.
No takes yet. Share an insight, caveat, or question.
Campos‐Obando et al. (2022) conducted a cohort in Coronary Artery Calcification (n=1,889). Serum phosphate levels vs. Lower serum phosphate levels was evaluated on Coronary artery calcification (CAC) score (β 0.93, 95% CI 0.07-1.79, p=0.034). Genetically predicted higher serum phosphate was causally associated with increased coronary artery calcification in the general population (β 0.93), even after excluding chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: